Why is "Amivantamab" trending?

Search Interest Perspective

• Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC - NEJM
• FDA Approves Subcutaneous Amivantamab (Rybrevant Faspro) for EGFR-Mutated NSCLC - Oncology News Central
• Sub-Q Amivantamab Offers Greater Convenience for Patients With EGFR-Mutated NSCLC: Estelamari Rodriguez, MD, MPH - AJMC
• Subcutaneous Amivantamab/Lazertinib: A New SOC in EGFR+ NSCLC? - CancerNetwork
• Redefining First-Line EGFR+ NSCLC with Subcutaneous Amivantamab & Lazertinib - Targeted Oncology
• FDA Approves Monthly First-Line Amivantamab and Hyaluronidase Dosing for EGFR-Mutated, Advanced NSCLC - OncLive
• FDA Approves Once-Monthly Dosing Schedule for Amivantamab and Hyaluronidase-lpuj - The ASCO Post
• FDA Approves Subcutaneous Amivantamab Monthly Dosing in EGFR+ NSCLC - Oncology Nursing News
• Amivantamab: A Deep Dive Into Its Mechanism, Clinical Data, and Expanding Role in EGFR-Driven Non–Small Cell Lung Cancer - Oncodaily
• Overall Survival with Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC - NEJM
• FDA Approves Once-Monthly SC Amivantamab Dosing in EGFR-Mutated NSCLC - AJMC
• FDA Approves Subcutaneous Amivantamab for EGFR+ NSCLC - OncLive
• FDA Approves Monthly Dosing for Subcutaneous Amivantamab in EGFR-Mutated NSCLC - Oncology News Central
• In a First, FDA Approves Monthly Subcutaneous Amivantamab for EGFR+ NSCLC - Targeted Oncology
• PALOMA-2 Shows Benefits of Subcutaneous Amivantamab in EGFR+ NSCLC - CancerNetwork
• First-Line Subcutaneous Amivantamab Plus Pembrolizumab Shows Efficacy in PD-L1+ HNSCC - OncLive
• Subcutaneous Amivantamab Earns Breakthrough Therapy Designation in HNSCC - CancerNetwork
• Dr Mehra on the Design of the OrigAMI-5 Trial of Amivantamab-Based Therapy in HNSCC - OncLive
• Sequencing After Amivantamab + Lazertinib and Cumulative Toxicity - CancerNetwork
• FDA Grants Breakthrough Therapy Designation to Subcutaneous Amivantamab for Advanced HNSCC - OncLive
• Dr Mehra on the Use of Amivantamab Plus Pembrolizumab and Carboplatin in HNSCC - OncLive
• Amivantamab for Lung Cancer: What Patients Need to Know - Oncodaily
• Subcutaneous Amivantamab Nabs Breakthrough Therapy Designation in HNSCC - Targeted Oncology
• Dr Sabari on the FDA Approval of Subcutaneous Amivantamab for EGFR-Mutant NSCLC - OncLive
• CNS Metastases in EGFR+ NSCLC: Data for Amivantamab Plus Lazertinib - OncLive
• FDA OKs Once-Monthly Subcutaneous Amivantamab Dose in EGFR+ NSCLC - CancerNetwork
• FDA Approves Subcutaneous Amivantamab: Joelle Fathi, DNP, Shares Key Nursing Implications - Cancer Nursing Today
• Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications - Cancer Therapy Advisor
• Amivantamab Regimen Maintains EGFR-Like Safety Profile in Metastatic CRC - Targeted Oncology
• Dr Mehra on the Efficacy of Subcutaneous Amivantamab Plus Pembrolizumab in HNSCC - OncLive
• Advancing Frontline Care for EGFR-Mutated NSCLC: Updates on Amivantamab With Lazertinib - Pharmacy Times
• Amivantamab: Overcoming Resistance in RAS/BRAF Metastatic CRC - Targeted Oncology
• FDA OKs Subcutaneous Amivantamab in EGFR+ NSCLC - CancerNetwork
• EGFR-MET Bispecific Antibody Shows Promise for Metastatic Head & Neck Cancer - Cleveland Clinic
• Subcutaneous Amivantamab Displays Activity in Recurrent/Metastatic HNSCC - CancerNetwork
• RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA stu - PR Newswire
• The Role of Amivantamab Plus Lazertinib in EGFR+ NSCLC - OncLive
• Dr Mehra on the Safety Profile of Subcutaneous Amivantamab in HNSCC - OncLive
• FDA Approval of Subcutaneous Amivantamab Offers Faster, Safer Option for EGFR-Mutated NSCLC - AJMC
• FDA Approves Subcutaneous Amivantamab for EGFR-Mutated NSCLC Indications - Targeted Oncology
• Initial Report Details Patient Experiences of Subcutaneous Amivantamab After IV Administration - Cancer Nursing Today
• Amivantamab Plus Lazertinib in Atypical EGFR -Mutated Advanced NSCLC - The ASCO Post
• Monthly RYBREVANT FASPRO (Amivantamab) Approved by FDA for EGFR-Mutated NSCLC - Oncodaily
• Dr Mehra on the FDA Breakthrough Therapy Designation for Amivantamab in HNSCC - OncLive
• FDA Approvals, Patient Selection, and SC Amivantamab - AJMC
• Amivantamab Combo Significantly Improves OS in Asian EGFR+ NSCLC Population - CancerNetwork
• Amivantamab–Lazertinib in EGFR -Mutated Advanced NSCLC - NEJM
• The Role of Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC Management - OncLive
• FDA Approves Once-Monthly Dosing Schedule for Amivantamab and Hyaluronidase-lpuj in EGFR-Mutated NSCLC - Pharmacy Times
• Amivantamab-Lazertinib Prolongs OS vs Osimertinib in EGFR -Mutant NSCLC - Cancer Therapy Advisor
• PAPILLON Study Evaluates PROs With Amivantamab Plus Chemotherapy in NSCLC - Cancer Nursing Today
• Data from PALOMA-3 for Subcutaneous Amivantamab in EGFR-Mutated NSCLC - OncLive
• Amivantamab Plus FOLFOX/FOLFIRI Demonstrates Strong, Durable Activity in mCRC - AJMC
• Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD - AJMC
• COCOON: Management of Dermatologic Side Effects of Amivantamab and Lazertinib for NSCLC - Cancer Nursing Today
• FDA Breakthrough Designation Expands Amivantamab Beyond Lung Cancer - BioPharm International
• PALOMA-2 Results for First-Line Subcutaneous Amivantamab in NSCLC - Targeted Oncology
• FDA Approval of Subcutaneous Amivantamab Is Significant Step Forward in NSCLC: Martin Dietrich, MD, PhD - AJMC
• Amivantamab Shows Potential to Unlock Curative Surgery in Metastatic CRC - Targeted Oncology
• U.S. FDA Approves RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Co-Formulated with ENHANZE® for the Treatment of Advanced EGFR-mutated Non-Small Cell Lung Cancer - PR Newswire
• FDA Approves RYBREVANT FASPRO as the First Subcutaneous Amivantamab Option for EGFR-Mutated NSCLC - Oncodaily
• Managing Amivantamab-Related Dermatologic Toxicities: What Oncology Nurses Should Know - Cancer Nursing Today
• Chemotherapy-Free Combo Prolongs Survival in EGFR-Mutated Non-Small Cell Lung Cancer - Oncology News Central
• Rybrevant Faspro Receives FDA Approval for All Amivantamab Indications - MPR - Medical Professionals Reference
• FDA Approves Amivantamab and Hyaluronidase-lpuj, Revolutionizing Lung Cancer Treatment With 5-Minute Subcutaneous Delivery - Pharmacy Times
• U.S. FDA Approval of RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) Enables the Simplest, Shortest Administration Time for a First-Line Combination Regimen when Combined with LAZCLUZE® (lazertinib) - MultiVu
• Exploring Time to Symptomatic Progression With Amivantamab Plus Chemotherapy in NSCLC Care - Cancer Nursing Today
• Amivantamab Plus Lazertinib vs Osimertinib in EGFR -Mutated NSCLC: Overall Survival in MARIPOSA - The ASCO Post
• Updated OS Data Reshape First- and Second-Line Treatment Selection in EGFR-Mutated Advanced NSCLC - OncLive
• FDA Approval Expands Access to Subcutaneous Amivantamab for Patients With EGFR-Mutated Advanced NSCLC - HMP Global Learning Network
• Amivantamab Linked to Diverse Dermatologic Adverse Events in Patients With Non-Small Cell Lung Cancer - Medscape
• Dr Lim on the Potential Role for Subcutaneous Amivantamab in EGFR-Mutant NSCLC - OncLive
• PALOMA-3 Trial Update: Subcutaneous Rybrevant FASPRO Plus Lazertinib Versus Intravenous Amivantamab-Based Regimens - Oncodaily
• Amivantamab Plus Lazertinib Yields OS Advantage in Asia Cohort of MARIPOSA Trial in EGFR-Mutated NSCLC - OncLive
• Amivantamab Plus Chemo Shows Durable Activity in RAS/BRAF WT mCRC - Physician's Weekly
• FDA Approves Amivantamab Plus Lazertinib as First-Line Treatment for Advanced EGFR-Mutated NSCLC - Docwire News
• COCOON Regimen Eases Amivantamab/Lazertinib Derm Toxicities in NSCLC - Oncology Nursing News
• FDA OKs Subcutaneous Amivantamab Across All NSCLC Indications - Oncology Nursing News
• Amivantamab and Hyaluronidase Approved as the only EGFR-targeted Therapy that can be Administered once a Month - Onco'Zine
• MARIPOSA Final OS Results in Asia Population Yield Meaningful Improvement in EGFR NSCLC - CancerNetwork
• Promising Efficacy Seen With Amivantamab Regimen in R/R Metastatic CRC - Targeted Oncology
• Safety Management With Amivantamab Plus Lazertinib in NSCLC - Oncology Nursing News
• Evaluating the Clinical Utility of Subcutaneous Amivantamab in the Treatment of EGFR-Mutant mNSCLC - CancerNetwork
• From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC - AJMC
• PALOMA-2 Trial Supports SC Amivantamab Q4W as a Patient-Centered Alternative to IV Therapy - AJMC
• SC Amivantamab Consistent With IV Formulation in EGFR-Mutated NSCLC - CancerNetwork
• Exploring Subcutaneous Amivantamab: Patient Preferences and Early Clinical Insights - Pharmacy Times
• Subcutaneous Amivantamab Shows Promise in EGFR-Mutated Lung Cancer - Pharmacy Times
• Case Report: The double-edged sword: cytokine release syndrome and rapid tumor response in a patient treated with amivantamab and chemotherapy - Frontiers
• Evaluating the Impact of Subcutaneous Amivantamab Administration - OncLive
• Subcutaneous Amivantamab for NSCLC Could Benefit Patients, Practices: Balazs Halmos, MD - AJMC
• Weighing Osimertinib vs Amivantamab-Lazertinib in Frontline EGFR NSCLC: Danny Nguyen, MD - AJMC
• Subcutaneous Amivantamab Allows for Potential Increases in Adherence, Treatment Options: Martin Dietrich, MD, PhD - AJMC
• Managing Early Adverse Events With Amivantamab + Lazertinib - CancerNetwork
• Amivantamab Plus Chemotherapy Delivers Durable Responses in RAS/BRAF Wild-Type mCRC: Filippo Pietrantonio, MD - AJMC
• Amivantamab shows promise in head and neck cancer - PharmaTimes
• NICE Endorses Chemo-Free First-Line Option for EGFR NSCLC - Medscape
• FDA clears Rybrevant Faspro as first SC option for EGFR-mutant NSCLC - FirstWord Pharma
• Subcutaneous amivantamab plus lazertinib produces similar results to IV regimen in NSCLC - Healio
• Estela Rodriguez on FDA Approval of Monthly Subcutaneous Amivantamab for EGFR-Mutant NSCLC - Oncodaily